INTRODUCTION {#s1}
============

The optimal patient selection criterion for postmastectomy radiotherapy (PMRT) in the management of breast cancer is a subject of ongoing debate. Previous randomized trials have established a clear guideline regarding the use PMRT in the setting of adjuvant chemotherapy \[[@R1]--[@R3]\]. However, whether PMRT can provide similar benefits in patients who had excellent pathological response after treatment with preoperative chemotherapy (NAC) is less clear. No results from prospective trials have been reported to evaluate PMRT\'s effect in the neoadjuvant setting. The available retrospective data suggest that the initial extent of disease clinically at presentation, the response of axillary lymph nodes to NAC, and the pathologic extent of residual disease are important factors to consider regarding the use of PMRT after NAC \[[@R4]--[@R6]\]. Thus, the National Cancer Institute (NCI) statement recommends that PMRT to the chest-wall and regional nodal basins should be considered for patients with clinical stage III disease or have histologically positive nodes after NAC \[[@R7]\]. Despite this, it remains unclear as to whether PMRT can provide improved patient outcomes for women with clinically node-positive, stage II to III breast cancer, but had a complete pathological nodal response (ypN0) after NAC. Previous studies aimed to address this question based on small retrospective cohorts have produced inconsistent results \[[@R4], [@R8]--[@R11]\]. A French group and another Korean study both showed that PMRT was not correlated with improved outcomes in clinical stage II-III patients with ypN0 after NAC \[[@R8], [@R10]\]. In contrast, research conducted at MD Anderson Cancer Center found that PMRT significantly improved local-regional recurrence (LRR) and cancer-specific survival (CSS) in clinical stage III breast cancer women even when they achieved a pathological complete response (pCR) following NAC \[[@R4], [@R11]\].

Therefore, there is a lack in consensus among practitioners regarding to the treatment recommendations of PMRT for clinically node-positive, stage II-III breast cancer patients with ypN0 after NAC. This was further demonstrated by a 2013 survey of 372 radiation oncologists which showed a split decision regarding treatment recommendations for clinical stage T2N1 patients who achieve ypN0 after NAC, with 49.9% of those surveyed recommending PMRT \[[@R12]\]. Given the conflicting results of small retrospective studies and lack of findings from randomized controlled trials, we analyzed a large national cohort of breast cancer patients, the National Cancer Database (NCDB), to identify the effectiveness of PMRT in terms of overall survival for clinically node-positive, stage II-III breast cancer patients with ypN0 after NAC.

MATERIALS AND METHODS {#s2}
=====================

Patient population {#s2_1}
------------------

We used data from the NCDB, which is a national hospital-based cancer registry jointly sponsored by the American College of Surgeons and the American Cancer Society, and collects data on about 70 % of newly diagnosed breast cancer cases in the United States. Data are coded and reported according to nationally established protocols coordinated under the auspices of the North American Association of Central Cancer Registries.

Data within the NCDB were rendered anonymous, so the study was exempt from review by the Johns Hopkins Medicine Institutional Review Board, and no consent was needed in this study.

A total of 2,807,541 breast cancer cases (International Classification of Diseases for Oncology, 3rd edition \[ICD-O-3\] histology codes 8000-8576, 8980-8981, and 9020/3 \[[@R13]\]), diagnosed between 1998 and 2012, were identified. The inclusion criteria were women 18 years or older, clinically node-positive and stage II-III (AJCC) breast cancer, treated with NAC and mastectomy with pathologically confirmed complete nodal response (ypN0). To ensure adequate follow-up time, we included cases diagnosed from 1998 through 2009. The timing of chemotherapy is coded in the NCDB as a temporal sequence with relation to definitive surgical therapy, allowing the accurate identification of NAC. Patients with positive or unknown surgical margin, pathological tumor size \> 5 cm after NAC, distant metastatic disease, or prior malignancy were excluded. Additional exclusion criteria included unknown clinical or pathological tumor/node stage, preoperative or intraoperative radiotherapy, or radiotherapy not for chest wall and draining lymphatics. This resulted in a cohort of 1580 patients of which 907 received PMRT and 673 patients did not. The primary endpoint for this study was overall survival (OS), which is defined as the time from diagnosis to the date of death from any cause. Some patients did not receive radiotherapy after surgery because of rapid death (due to disease progression or post-operative complications) or loss of follow-up. To minimize this potential bias between groups, we excluded patients who died or lost to follow-up within 3 months after mastectomy: 4 (0.4%) in the irradiated group and 16 (2.4%) in the non-irradiated group. This left 1560 patients for final analysis.

Statistical analysis {#s2_2}
--------------------

### Primary analysis {#s2_2_1}

Characteristics of the entire study population were presented according to PMRT treatment. The demographic and clinicopathological characteristics were compared between the two groups using the χ^2^ test. OS curves were constructed using the Kaplan-Meier method and compared between the two groups using the log-rank test. Multivariate Cox proportional hazard model was applied to assess the independent prognostic effect of PMRT or other factors. Likelihood ratio test was used to select the best multivariate Cox model. We also performed subgroup analyses to identify the role of PMRT on OS in various subgroups of patients.

### Sensitivity analysis using imputation and propensity score {#s2_2_2}

Propensity score-based sensitivity analysis was done to minimize selection bias or a lack of covariate balance. In the NCDB database, some key variables (eg. histologic grade) contain missing data, which may result in biases. To compensate for this, multiple imputation methods by chained equations \[[@R14]--[@R16]\] to account for the missing values of several variables was performed before the propensity score matching. NCDB has neither ER/PR records before 2004, nor Chalson/Deyo score before 2003, we can not assume unknown ER/PR status and Chalson/Deyo score are missing at random. Thus, we conducted the imputation to accommodate missing data for insurance status, histologic grade, number of examined lymph nodes, chemotherapy type, and use of hormone therapy, but not for ER/PR status or Chalson/Deyo score. A probabilistic rule based on regression models for each covariable with the other covariables serving as predictors was used to impute possible values for individual missing values. A full dataset was created after imputing for 10 times using "complete" function in MICE package \[[@R16], [@R17]\].

For the entire study cohort and individual subgroups, we performed logistic regression to select demographic and clinicopathological variables associated with the implementation of PMRT. All variables with a univariate *P* value ≤0.20 were eligible for inclusion in the logistic regression model. The final multivariate logistic model was used to calculate the propensity score for each individual, which is the probability of the patient being treated with PMRT. Patients who received PMRT were matched to patients who did not receive PMRT by propensity score ± 0.1 in a 1:1 ratio. The quality of the matching was checked by calculating the standardized difference for each covariate, assuming that the balance was achieved if the standardized difference was less than 0.1 \[[@R18]\]. Univariate and/or multivariate survival analyses were performed in the propensity score-matched populations using the same methods as those in the primary analysis.

Statistical analyses were conducted using STATA 12.0 software (StataCrop, College Station, TX) or R software (R Core Team 2014 \[[@R19]\]). All statistical tests were two-sided, and statistical significance was defined as *P* \< 0.05.

RESULTS {#s3}
=======

Patient and treatment characteristics {#s3_1}
-------------------------------------

Of the 1560 clinically node-positive, stage II-III breast cancer patients who had complete pathological nodal response after NAC and mastectomy, 903 (57.9%) received PMRT and 657 (42.1%) did not. All the patients had negative surgical margins. Table [1](#T1){ref-type="table"} presents the comparisons of demographic, clinicopathological, and treatment characteristics between these two cohorts of patients. When compared with patients who did not receive PMRT, irradiated patients had less comorbidities, more advanced clinical tumor stage, nodal stage, or AJCC stage, more regional lymph nodes examined, and less unknown ER/PR status, and received more multi-agent chemotherapy or hormone therapy (*P* \< 0.01 for all comparisons). No difference was found between the two groups with respect to age, race, insurance status, pathological tumor stage (after NAC), or histologic grade. For the patients treated with PMRT, radiation targets included chest wall and draining lymphatics, with or without a chest wall boost. The median dose of radiation was 50.4 Gy.

###### Characteristics of the whole study population (*n* = 1560)

  Characteristics                           No PMRT (*n* = 657)          PMRT (*n* = 903)   *P*          
  ----------------------------------------- --------------------- ------ ------------------ ----- ------ ---------
  Age, years                                                                                      NS     
   Median (range)                           50 (20-86)                   50 (22-88)                      
   ≤40                                      143                   21.8                      203   22.5   
   41-60                                    386                   58.7                      545   60.3   
   \>60                                     128                   19.5                      155   17.2   
  Race                                                                                                   NS
   White                                    494                   75.2                      693   76.7   
   Black                                    121                   18.4                      162   17.9   
   Asian or other                           42                    6.4                       48    5.3    
  Insurance status                                                                                       NS
   Not insured                              31                    4.7                       49    5.4    
   Private insurance                        426                   64.8                      620   68.7   
   Public insurance                         186                   28.3                      227   25.1   
   Unknown                                  14                    2.1                       7     0.8    
  Chalson/Deyo score                                                                                     \<0.001
   0                                        552                   84.0                      797   88.3   
   1                                        44                    6.7                       83    9.2    
   2                                        10                    1.5                       7     0.8    
   Unknown                                  51                    7.8                       16    1.8    
  Year of diagnosis                                                                                      \<0.001
   1998-2003                                90                    13.7                      56    6.2    
   2004-2009                                567                   86.3                      847   93.8   
  Histological type                                                                                      
   Ductal                                   540                   82.2                      718   79.6   NS
   Lobular                                  50                    7.6                       61    6.7    
   Other                                    67                    10.2                      124   13.7   
  No. of nodes examined                                                                                  0.009
   Median (range)                           11 (1-46)                    12 (1-46)                       
   1-10                                     317                   48.2                      379   42.0   
   \>10                                     320                   48.7                      507   56.1   
   Unknown                                  20                    3.0                       17    1.9    
  Clinical T-stage                                                                                       \<0.001
   T1                                       79                    12.0                      55    6.1    
   T2                                       276                   42.0                      254   28.1   
   T3                                       170                   25.9                      279   30.9   
   T4                                       132                   20.1                      315   34.9   
  Clinical N-stage                                                                                       \<0.001
   N1                                       530                   80.7                      651   72.1   
   N2                                       90                    13.7                      161   17.8   
   N3                                       37                    5.6                       91    10.1   
  Clinical AJCC stage                                                                                    \<0.001
   II                                       325                   49.5                      231   25.6   
   III                                      332                   50.5                      672   74.4   
  Pathologic T-stage (after NAC)                                                                         NS
   T0/Tis                                   277                   42.2                      399   44.2   
   T1                                       221                   33.6                      315   34.9   
   T2                                       159                   24.2                      189   20.9   
  Histologic grade                                                                                       NS
   Well or moderately                       161                   24.5                      199   22.0   
   Poorly or undifferentiated               413                   62.9                      613   67.9   
   Unknown                                  83                    12.6                      91    10.1   
  ER^[\*](#tfn_001){ref-type="table-fn"}^                                                                \<0.001
   Negative                                 330                   50.2                      503   55.7   
   Positive                                 208                   31.7                      331   36.7   
   Unknown                                  119                   18.1                      69    7.6    
  PR^[\*](#tfn_001){ref-type="table-fn"}^                                                                \<0.001
   Negative                                 379                   57.7                      563   62.3   
   Positive                                 159                   24.2                      270   29.9   
   Unknown                                  119                   18.1                      70    7.8    
  Chemotherapy type                                                                                      \<0.001
   Single-agent                             13                    2.0                       4     0.4    
   Multi-agent                              588                   89.5                      881   97.6   
   Unknown if single or multi-              56                    8.5                       18    2.0    
  Hormone therapy                                                                                        \<0.001
   No                                       449                   68.3                      539   59.7   
   Yes                                      181                   27.5                      335   37.1   
   Unknown                                  27                    4.1                       29    3.2    

Abbreviations: PMRT, postmastectomy radiotherapy; NS, not significant (*P* \>0.05);

AJCC, American Joint Committee on Cancer (fifth or sixth edition); NAC, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor

ER or PR groups include those with borderline results.

Survival analyses for the whole population {#s3_2}
------------------------------------------

Overall, the median follow-up was 56.0 months (range, 6.14-185.4 months). At the cutoff date for the survival analysis (December 2013), a total of 139 (15.4%) and 124 (18.9%) patients died in the PMRT and no PMRT group, respectively. The 5-year OS rates in the two groups were not significantly different (84.6% for PMRT *vs* 81.7% for no PMRT, *P* = 0.120, Figure [1](#F1){ref-type="fig"}). PMRT also showed no association with a difference in OS by multivariate analysis (PMRT *vs* no PMRT: HR 0.820, 95% CI 0.630-1.068, Table [2](#T2){ref-type="table"}). Factors found to be significant for worse OS by multivariate analysis included: age older than 60 years, white or black race, public insurance (compared with private insurance), higher histologic grade, fewer than 10 axillary nodes examined, clinical T4 tumor, clinical stage III disease, residual pathologic T2 tumor, and lack of hormone therapy (*P* \< 0.05 for all comparisons, Table [2](#T2){ref-type="table"}).

![Rate of overall survival for the entire cohort of patients treated with PMRT (*n* = 903) and without PMRT (*n* = 657)](oncotarget-07-24848-g001){#F1}

###### Multivariate analysis of OS for the whole study population (*n* = 1560)

  Factors                          HR          95% CI         *P*
  -------------------------------- ----------- -------------- -----------
  Age, years                                                  
   ≤40                             Reference                  
   41-60                           1.209       0.857-1.706    0.281
   \>60                            1.692       1.122-2.553    **0.012**
  Race                                                        
   White                           Reference                  
   Black                           0.965       0.701-1.329    0.829
   Asian or other                  0.394       0.174-0.894    **0.026**
  Insurance status                                            
   Private insurance               Reference                  
   Public insurance                1.468       1.093-1.971    **0.011**
  Not insured                      1.155       0.645-2.068    0.627
  Unknown                          1.176       0.423-3.270    0.756
  Histologic grade                                            
   Well differentiated             Reference                  
   Moderately differentiated       9.749       1.331-71.425   **0.025**
   Poorly or undifferentiated      7.760       1.066-56.489   **0.043**
   Unknown                         9.221       1.239-68.657   **0.030**
  Examined regional nodes number                              
   0-10                            Reference                  
   \>10                            0.770       0.598-0.991    **0.043**
   Unkown                          1.196       0.576-2.482    0.631
  Clinical T-stage                                            
   T1                              Reference                  
   T2                              0.692       0.419-1.141    0.149
   T3                              1.575       0.784-3.167    0.202
   T4                              2.808       1.395-5.649    **0.004**
  Clinical AJCC stage                                         
   II                              Reference                  
   III                             2.193       1.197-4.017    **0.011**
  Pathologic T-stage (after NAC)                              
   T0/Tis                          Reference                  
   T1                              1.275       0.943-1.724    0.115
   T2                              1.599       1.160-2.205    **0.004**
  Hormone therapy                                             
   No                              Reference                  
   Yes                             0.647       0.441-0.951    **0.027**
   Unknown                         0.618       0.300-1.273    0.192
  PMRT                                                        
   No                              Reference                  
   Yes                             0.820       0.630-1.068    0.141

Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer (fifth or sixth edition); NAC, neoadjuvant chemotherapy; PMRT, postmastectomy radiotherapy

However, subgroup analyses demonstrated PMRT significantly improved OS in patients with clinical stage IIIB/IIIC disease or T3/T4 tumor, or residual invasive breast tumor after NAC (*P* \< 0.05 for all comparisons; Table [3](#T3){ref-type="table"}, Figure [2A to 2C](#F2){ref-type="fig"}).

![**Rate of overall survival for patients with A.** clinical IIIB/IIIC disease, **B.** clinical T3/T4 tumor, or **C.** pathologic T1/T2 tumor after NAC who were treated with PMRT and without PMRT.](oncotarget-07-24848-g002){#F2}

###### Subgroup analyses for the effect of PMRT on the 5-year OS rate in the primary analysis

  Factors                                                 5-year OS Rate (%)   *P*    
  ------------------------------------------------------- -------------------- ------ -----------
  Age                                                                                 
   ≤40                                                    90.2                 86.7   0.136
   41-60                                                  82.8                 85.4   0.151
   \>60                                                   67.8                 78.9   0.053
  Clinical AJCC stage                                                                 
   II                                                     83.9                 86.5   0.424
   IIIA                                                   86.8                 89.5   0.247
   IIIB/IIIC                                              71.2                 79.3   **0.027**
  Clinical T-stage                                                                    
   T1/T2                                                  86.0                 87.8   0.329
   T3/T4                                                  76.6                 82.8   **0.025**
  Clinical N-stage                                                                    
   N1                                                     81.7                 84.8   0.191
   N2/N3                                                  81.5                 84.0   0.359
  Pathologic T-stage (after NAC)                                                      
   T0/Tis                                                 86.9                 86.0   0.891
   T1/T2                                                  78.0                 83.6   **0.041**
  Hormone receptor^[\*](#tfn_002){ref-type="table-fn"}^                               
   Negative                                               82.6                 83.4   0.587
   Positive                                               82.9                 87.6   0.178

Abbreviations: PMRT, postmastectomy radiotherapy; OS, overall survival; AJCC, American Joint Committee on Cancer (fifth or sixth edition); NAC, neoadjuvant chemotherapy

We created a joint hormone receptor status using estrogen receptor (ER) and progesterone receptor (PR) status. Those with either ER or PR positive status (ER or PR positive groups included those with borderline results) were grouped as hormone receptor positive, and those with ER and PR negative status were grouped as hormone receptor negative.

Survival analyses for propensity score-matched populations {#s3_3}
----------------------------------------------------------

Since patients who received PMRT differed from patients who did not receive PMRT, we performed propensity score analysis as a sensitivity analysis to ensure that previous results were not due to lack of baseline covariate balance. Before the propensity score analysis, we used multiple imputation methods to account for the missing values of several variables. Sensitivity analysis showed that the effects of PMRT on OS were quite similar before and after imputation (data not shown).

Of the entire study population, we matched 523 pairs of patients by propensity scores. Table [4](#T4){ref-type="table"} shows the characteristics and standardized mean differences of all covariates between the two groups before and after matching. Univariate and multivariate analyses consistently showed no statistical effect of PMRT on OS (*P* = 0.167; PMRT *vs* no PMRT: HR 0.847, 95% CI 0.632-1.136, [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}, and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We also matched the patients who received PMRT to those who did not, by propensity scores among distinct subgroups of patients based on the above primary subgroup survival analyses. Subgroup analyses for propensity score-matched populations identified PMRT improved OS in patients with clinical stage IIIB/IIIC disease, T3/T4 tumor, or residual invasive breast cancer after NAC, which is the same subset of patients as those defined by the primary subgroup analyses (*P* \< 0.05 for all comparisons; Table [5](#T5){ref-type="table"}, [Supplementary Figure 2A to 2C](#SD1){ref-type="supplementary-material"}).

###### Characteristics and standardised mean differences of covariates among patients with or without PMRT before and after propensity-score matching

  Characteristics                           Before matching (*n* = 1560)   After mathching (*n* = 1046)                          
  ----------------------------------------- ------------------------------ ------------------------------ -------- ------ ------ --------
  Age, years                                                                                                                     
   ≤40                                      21.8                           22.5                           0.017    22.0   22.7   0.018
   41-60                                    58.7                           60.3                           0.032    58.5   60.4   0.039
   \>60                                     19.5                           17.2                           −0.060   19.5   16.9   −0.069
  Race                                                                                                                           
   White                                    75.2                           76.7                           0.036    75.7   74.0   −0.041
   Black                                    18.4                           17.9                           −0.012   18.4   20.5   0.055
   Asian or other                           6.4                            5.3                            −0.047   5.9    5.5    −0.017
  Insurance status                                                                                                               
   Not insured                              5.1                            5.6                            0.054    5.7    5.3    0.017
   Private insurance                        66.4                           68.9                           0.020    66.9   67.7   −0.017
   Public insurance                         28.5                           25.5                           −0.069   27.4   27.0   −0.009
  Chalson/Deyo score                                                                                                             
   0                                        84.0                           88.3                           0.132    87.6   87.2   −0.012
   1                                        6.7                            9.2                            0.086    7.5    8.6    0.040
   2                                        1.5                            0.8                            −0.085   1.1    1.1    0.000
   Unknown                                  7.8                            1.8                            −0.454   3.8    3.1    −0.058
  Year of diagnosis                                                                                                              
   1998-2003                                13.7                           6.2                            −0.311   9.2    8.6    −0.024
   2004-2009                                86.3                           93.8                           0.311    90.8   91.4   0.024
  Histological type                                                                                                              
   Ductal                                   82.2                           79.6                           −0.064   81.2   81.4   0.005
   Lobular                                  7.6                            6.7                            −0.039   7.3    7.3    0.000
   Other                                    10.2                           13.7                           0.103    11.5   11.3   −0.006
  No. of nodes examined                                                                                                          
   1-10                                     49.8                           42.9                           −0.140   49.0   45.1   −0.077
   \>10                                     50.2                           57.1                           0.140    51.0   54.9   0.077
  Clinical T-stage                                                                                                               
   T1                                       12.0                           6.1                            −0.248   8.8    8.6    −0.008
   T2                                       42.0                           28.1                           −0.309   39.0   39.2   0.004
   T3                                       25.9                           30.9                           0.109    28.5   27.9   −0.012
   T4                                       20.1                           34.9                           0.310    23.7   24.3   0.012
  Clinical N-stage                                                                                                               
   N1                                       80.7                           72.1                           −0.191   76.9   76.9   0.000
   N2                                       13.7                           17.8                           0.108    16.0   14.5   −0.040
   N3                                       5.6                            10.1                           0.148    7.1    8.6    0.051
  Clinical AJCC stage                                                                                                            
   II                                       49.5                           25.6                           −0.547   41.9   40.3   −0.035
   III                                      50.5                           74.4                           0.547    58.1   59.7   0.035
  Pathologic T-stage (after NAC)                                                                                                 
   T0/Tis                                   42.2                           44.2                           0.041    43.2   40.9   −0.046
   T1                                       33.6                           34.9                           0.026    33.7   34.0   0.008
   T2                                       24.2                           20.9                           −0.080   23.1   25.1   0.047
  Histologic grade                                                                                                               
   Well                                     2.7                            2.7                            −0.005   2.5    2.9    0.024
   Moderatedly                              25.3                           22.1                           −0.075   26.0   25.6   −0.009
   Poorly or undifferentiated               72.0                           75.2                           0.074    71.5   71.5   0.000
  ER^[\*](#tfn_003){ref-type="table-fn"}^                                                                                        
   Negative                                 50.2                           55.7                           0.110    53.7   51.8   −0.038
   Positive                                 31.7                           36.7                           0.104    34.6   37.1   0.052
   Unknown                                  18.1                           7.6                            −0.394   11.7   11.1   −0.022
  PR^[\*](#tfn_003){ref-type="table-fn"}^                                                                                        
   Negative                                 57.7                           62.3                           0.096    61.2   59.5   −0.035
   Positive                                 24.2                           29.9                           0.124    27.2   29.2   0.046
   Unknown                                  18.1                           7.8                            −0.387   11.6   11.3   −0.014
  Chemotherapy type                                                                                                              
   Single-agent                             3.0                            0.5                            −0.391   0.6    0.8    0.029
   Multi-agent                              97.0                           99.5                           0.391    99.4   99.2   −0.029

Abbreviations: PMRT, postmastectomy radiotherapy; NS, not significant (*P* \>0.05);

AJCC, American Joint Committee on Cancer (fifth or sixth edition); NAC, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor

ER or PR groups include those with borderline results.

###### Subgroup analyses for the effect of PMRT on the 5-year OS rate in the sensitivity analysis (for the propensity score-matched patients)

  Factors                                                 5-year OS Rate (%)   *P*    
  ------------------------------------------------------- -------------------- ------ -----------
  Age                                                                                 
   ≤40                                                    92.3                 87.4   0.296
   41-60                                                  82.8                 86.8   0.076
   \>60                                                   67.8                 77.8   0.138
  Clinical AJCC stage                                                                 
   II                                                     80.7                 86.0   0.236
   IIIA                                                   53.1                 51.9   0.687
   IIIB/IIIC                                              71.6                 80.4   **0.046**
  Clinical T-stage                                                                    
   T1/T2                                                  85.1                 85.5   0.420
   T3/T4                                                  76.9                 81.7   **0.049**
  Clinical N-stage                                                                    
   N1                                                     83.4                 84.9   0.247
   N2/N3                                                  81.2                 80.3   0.946
  Pathologic T-stage (after NAC)                                                      
   T0/Tis                                                 91.2                 86.0   0.645
   T1/T2                                                  78.0                 84.6   **0.032**
  Hormone receptor^[\*](#tfn_004){ref-type="table-fn"}^                               
   Negative                                               83.7                 80.4   0.580
   Positive                                               81.5                 85.6   0.352

Abbreviations: PMRT, postmastectomy radiotherapy; OS, overall survival; AJCC, American Joint Committee on Cancer (fifth or sixth edition); NAC, neoadjuvant chemotherapy

We created a joint hormone receptor status using estrogen receptor (ER) and progesterone receptor (PR) status. Those with either ER or PR positive status (ER or PR positive groups included those with borderline results) were grouped as hormone receptor positive, and those with ER and PR negative status were grouped as hormone receptor negative.

DISCUSSION {#s4}
==========

NAC is being used more frequently for clinical stage II or III breast cancer patients, raising issues regarding to the subsequent locoregional treatment, such as radiotherapy and sentinel node biopsy. However, the role of PMRT in clinically node-positive, stage II-III patients with negative pathological nodes (ypN0) after NAC, remains unclear. The current study included a large, registry-based, national patient cohort, with the aim to address this question. Our findings suggest that PMRT improves patient OS, but its benefit appears to be limited to selected patients with clinical stage IIIB/IIIC disease, clinical T3/T4 tumor, or residual invasive breast tumor after NAC.

One of the main effects of NAC is its potential to downstage the pathological extent of disease. Previous studies showed 20% to 40% of breast cancer patients with clinically positive nodes at diagnosis can achieve a complete pathological nodal response after NAC \[[@R20], [@R21]\]. This pathological downstaging presents a unique challenge to treatment decision-making. Further complicating the issue is the lack of definitive data in the literature. Studies regarding the effectiveness of PMRT among women with clinically node-positive, stage II-III disease who downstaged to ypN0 following NAC were all based on retrospective analysis of small patient cohorts, and had conflicting results. A study from MD Anderson Cancer Center found that PMRT reduced LRR for patients with clinical stage III or IV disease and subsequently achieved a pCR to NAC, but no difference in LRR rates was observed in patients with clinical stage I-II disease with a pCR \[[@R4]\]. Their updated single-institutional experience, including 106 patients with a pCR in the breast and regional lymph nodes to NAC, indicated similar results (selected patients with clinical stage III disease with a pCR after NAC can benefit from PMRT) \[[@R11]\]. However, a French study showed that PMRT was not associated with improved local recurrence-free survival, disease-free survival or OS in women with ypN0 after NAC \[[@R9]\]. Similarly, a multicenter retrospective study (*n* = 151) also reported that PMRT had no effectiveness in clinical stage II-III Korean breast cancer patients with ypN0 following NAC\[[@R10]\]. Since radiotherapy for breast cancer has toxicities including cardiac complications, pneumonitis, and lymphedema \[[@R22]\], and PMRT may lead to additional plastic surgeries for completion of breast reconstruction, the authors recommended the omission of PMRT in clinical stage II-III patients with ypN0 after NAC. Our study, based on a large patient cohort, on the other hand, is in support with the observations made by the MD Anderson studies. Unlike the French and Korean study, which had inherent shortcomings such as limited sample size, and multiple unbalanced baseline characteristics between groups, the current study represent the largest and utilized the most contemporary analysis to address this issue. The large sample size and more robust sensitivity analyses using imputation and propensity score matching enabled us to better quantify the survival benefit of PMRT for multiple subgroups of patients with minimal potential biases.

Clinically node-positive, stage II-III breast cancer patients who had complete nodal response to NAC after mastectomy represent a heterogeneous collection of patients with a wide range of demographic, clinicopathologic and treatment response related characteristics. Therefore, an important question to ask is which specific subset of these patient would most benefit from additional PMRT. Despite clinical disease stage before NAC, are there any other factors (such as ER/PR status, or pathologic tumor stage after NAC) will influence the patient selection for PMRT among these ypN0 women? A combined analysis of two National Surgical Adjuvant Breast and Bowel Project (NSABP) trials (B-18 and B-27) concluded that in addition to initial tumor characteristic before NAC, pathologic response in the breast and the axillary lymph nodes had a major impact on the rates and patterns of LRR; so the pathologic tumor stage and nodal status after NAC might be useful factors for predicting the optimal use of postmastectomy radiation in patients treated with preoperative chemotherapy \[[@R23]\]. Other studies reported that lymphovascular invasion (LVI) was another possible effect modifier that can aid in selecting patients who have a ypN0 following NAC but would benefit from PMRT \[[@R9], [@R24]\]. Based on our findings, it appears that patients with more locally advanced disease at presentation (clinical IIIB/IIIC disease or T3/T4 tumor), or with residual invasive breast tumor after NAC (who did not achieve a pCR in the breast) may benefit PMRT as part of their adjuvant therapy even if they downstaged to ypN0 following NAC. However, despite our best attempt to reduce the potential bias and confounding effects from NCDB and the retrospective nature of our study, definitive evidence from randomized controlled trials like NSABP B-51 are required to confirm our results, or identify further subsets of patients who may benefit from PMRT.

Despite several strengths of this study including its multicenter large sample size, refined subgroup analyses, sensitivity analysis using multiple imputation and propensity score matching, several limitations should be acknowledged. First, the NCDB has no recurrence data, so we can not affirm a lack of benefit from PMRT for some subgroups of women simply based on OS alone. This is especially the case for patients with earlier clinical stage disease, where disease control and free from recurrence would more likely be the primary endpoint of interest. Second, the NCDB suffers from lack of HER2 status and detailed histological evaluation including the information of LVI, Ki67, and the incompleteness of ER/PR status in a small portion of patients. All these factors are known to have prognostic value and can predict treatment response. Third, because of the limited number of patients (reduced statistical power) in several subgroup analyses, we cannot conclude lack of survival benefit from PMRT, particularly for patients who were diagnosed before 41 years or after 60 years. Finally, although our study has a median follow-up time of 56.0 months, longer follow-up might help explore other subsets of women who can benefit from PMRT, especially for low-risk patients.

CONCLUSIONS {#s5}
===========

In conclusion, we provided important evidence that among clinically node-positive, stage II-III breast cancer patients with ypN0 following NAC, PMRT can improve overall survival in patients with clinical T3/T4 tumor or stage IIIB/IIIC disease, and in patients with residual invasive breast tumor after NAC. Our study may help oncologists to recommend PMRT for selected patients who downstaged to ypN0 following NAC. Results from further prospective studies such as the ongoing NSABP B-51 trial are needed, in order to confirm our findings and define other specific subgroups of women with pathological negative nodes following NAC who would benefit from PMRT, particularly in the relatively low-risk patients.

SUPPLEMENTARY MATERIAL FIGURES AND TABLE {#s6}
========================================

The data used in the study was derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology used or the conclusions drawn from these data by the investigator.
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